Blinatumomab (Blincyto®)

Blinatumomab (Blincyto®)

A Medical Need Program of Blinatumomab for the treatment of adults with B-precursor acute lymphoblastic leukemia (ALL) in complete hematological remission defined as less than or equal to 5% blasts in the bone marrow after at least three intense chemotherapy blocks and presence of minimal residual disease (MRD) at a level ≥ 10-4.

A Medical Need Program of Blinatumomab for the Treatment of Relapsed / Refractory (R/R)B-precursor Acute Lymphoblastic Leukemia (ALL).